Femoston 2/10mg film-coated tablets Malta - English - Medicines Authority

femoston 2/10mg film-coated tablets

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - estradiol, dydrogesterone - film-coated tablet - estradiol 2 mg dydrogesterone 10 mg - sex hormones and modulators of the genital system

Femoston 1/10mg film-coated tablets Malta - English - Medicines Authority

femoston 1/10mg film-coated tablets

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - estradiol, dydrogesterone - film-coated tablet - estradiol 1 mg dydrogesterone 10 mg - sex hormones and modulators of the genital system

FEMOSTON 1/10 Ireland - English - HPRA (Health Products Regulatory Authority)

femoston 1/10

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 1 mg, 10 m milligram

FEMOSTON 2/10 Ireland - English - HPRA (Health Products Regulatory Authority)

femoston 2/10

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 2 mg, 10 m milligram

Femoston-conti 1mg/5mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

femoston-conti 1mg/5mg tablets

viatris uk healthcare ltd - dydrogesterone; estradiol - oral tablet - 5mg ; 1mg

Femoston-conti 0.5mg/2.5mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

femoston-conti 0.5mg/2.5mg tablets

viatris uk healthcare ltd - estradiol; dydrogesterone - oral tablet - 500microgram ; 2.5mg

Femoston 2/10 New Zealand - English - Medsafe (Medicines Safety Authority)

femoston 2/10

viatris limited - estradiol 2mg; dydrogesterone 10mg; estradiol 2mg - tablet - active: estradiol 2mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch opadry orange oy-23000 active: dydrogesterone 10mg estradiol 2mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch opadry yellow oy-7915 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use.